Metabolic modulator comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Vitamin E is a group of eight compounds related in molecular structure that includes four tocopherols and four tocotrienols. The tocopherols function as fat-soluble antioxidants which may help protect cell membranes from reactive oxygen species. Vitamin E is classified as an essential nutrient for humans. Various government organizations recommend that adults consume between 3 and 15 mg per day, while a 2016 worldwide review reported a median dietary intake of 6.2 mg per day. Sources rich in vitamin E include seeds, nuts, seed oils, peanut butter, vitamin E–fortified foods, and dietary supplements. Symptomatic vitamin E deficiency is rare, usually caused by an underlying problem with digesting dietary fat rather than from a diet low in vitamin E. Deficiency can cause neurological disorders. Tocopherols and tocotrienols both occur in α (alpha), β (beta), γ (gamma), and δ (delta) forms, as determined by the number and position of methyl groups on the chromanol ring. All eight of these vitamers feature a chromane double ring, with a hydroxyl group that can donate a hydrogen atom to reduce free radicals, and a hydrophobic side chain that allows for penetration into biological membranes. Both natural and synthetic tocopherols are subject to oxidation, so dietary supplements are esterified, creating tocopheryl acetate, (or other forms such as succinate or palmitate) for stability purposes.
Limosilactobacillus fermentum is a Gram-positive species in the heterofermentative genus Limosilactobacillus. It is associated with active dental caries lesions. It is also commonly found in fermenting animal and plant material including sourdough and cocoa fermentation. Some strains of lactobacilli formerly mistakenly classified as L. fermentum (such as RC-14) have since been reclassified as Limosilactobacillus reuteri.
239Pu is one of the three fissile materials used for the production of nuclear weapons and in some nuclear reactors as a source of energy. The other fissile materials are uranium-235 and uranium-233. 239Pu is virtually nonexistent in nature. It is made by bombarding uranium-238 with neutrons. Uranium-238 is present in quantity in most reactor fuel; hence 239Pu is continuously made in these reactors. Since 239Pu can itself be split by neutrons to release energy, 239Pu provides a portion of the energy generation in a nuclear reactor.
It was realised that both hypocalcin and teleocalcin are the same. It was conclusively shown that the isolated compound was the factor that reduces calcium level in these fishes. In 1990, the exact chemical composition and biosynthesis war worked out, and was given the name "stanniocalcin" as it was found to be exclusively produced by the corpuscles of Stannius. The complete amino acid sequence was described in 1995.
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
Sources: en.wikipedia.org
==== Recent vaccines development in aquaculture ==== There are 24 vaccines available and one for lobsters. The first vaccine was used in the USA against enteric red mouth in 1976. However, there are 19 companies and some small stakeholders are producing vaccines for aquaculture nowadays. The novel approaches are a way forward to prevent the loss of 10% of aquaculture through disease. Genetically modified vaccines are not being used in the EU due to societal concerns and regulations. Meanwhile, DNA vaccines are now authorised in the EU. There are challenges in fish vaccine development, immune response due to lack of potent adjuvants. Scientists are considering microdose application in future. But there are also opportunities in aquaculture vaccinology due to the low cost of technology, regulations change and novel antigen expression and delivery systems. In Norway subunit vaccine (VP2 peptide) against infectious pancreatic necrosis is being used. In Canada, a licensed DNA vaccine against Infectious hematopoietic necrosis has been launched for industry use. Fish have large mucosal surfaces, so the preferred route is immersion, intraperitoneal and oral respectively. Nanoparticles are in progress for delivery purposes. The common antibodies produced are IgM and IgT. Normally booster is not required in fish because more memory cells are produced in response to the booster rather than an increased level of antibodies. mRNA vaccines are alternative to DNA vaccines because they are more safe, stable, easily producible at a large scale and mass immunization potential.
Seeing an opportunity in Napoleon I's historic defeat, Prussia, Sweden and several other German states switched sides, joining Russia, the United Kingdom and others opposing Napoleon. Napoleon vowed that he would create a new army as large as the one he had sent into Russia, and quickly built up his forces in the east from 30,000 to 130,000 and eventually to 400,000. Napoleon inflicted 40,000 casualties on the Allies at Lützen (2 May 1813) and Bautzen (20–21 May 1813). Both battles involved forces of over 250,000, making them some of the largest conflicts of the wars so far. Klemens von Metternich in November 1813 offered Napoleon the Frankfurt proposals. They would allow Napoleon to remain Emperor but France would be reduced to its "natural frontiers" and lose control of most of Italy and Germany and the Netherlands. Napoleon still expected to win the wars, and rejected the terms. By 1814, as the Allies were closing in on Paris, Napoleon I did agree to the Frankfurt proposals, but it was too late and he rejected the new harsher terms proposed by the Allies.
=== MeSH D12.644.456 – oligopeptides === MeSH D12.644.456.050 – amanitins MeSH D12.644.456.073 – angiotensins MeSH D12.644.456.073.021 – angiotensin i MeSH D12.644.456.073.041 – angiotensin ii MeSH D12.644.456.073.041.050 – angiotensin amide MeSH D12.644.456.073.041.800 – saralasin MeSH D12.644.456.073.041.815 – 1-sarcosine-8-isoleucine angiotensin ii MeSH D12.644.456.073.055 – angiotensin iii MeSH D12.644.456.073.070 – angiotensinogen MeSH D12.644.456.120 – antipain MeSH D12.644.456.193 – bradykinin MeSH D12.644.456.193.400 – kallidin MeSH D12.644.456.241 – caerulein MeSH D12.644.456.270 – chalones MeSH D12.644.456.300 – delta sleep-inducing peptide MeSH D12.644.456.345 – dipeptides MeSH D12.644.456.345.159 – anserine MeSH D12.644.456.345.190 – aspartame MeSH D12.644.456.345.331 – carnosine MeSH D12.644.456.345.360 – enalapril MeSH D12.644.456.345.360.300 – enalaprilat MeSH D12.644.456.345.575 – glycylglycine MeSH D12.644.456.345.600 – lisinopril MeSH D12.644.456.400 – n-formylmethionine leucyl-phenylalanine MeSH D12.644.456.448 – glutathione MeSH D12.644.456.448.500 – glutathione disulfide MeSH D12.644.456.448.750 – s-nitrosoglutathione MeSH D12.644.456.460 – gonadorelin MeSH D12.644.456.460.150 – buserelin MeSH D12.644.456.460.315 – goserelin MeSH D12.644.456.460.480 – leuprolide MeSH D12.644.456.460.600 – nafarelin MeSH D12.644.456.460.800 – triptorelin MeSH D12.644.456.580 – leupeptins MeSH D12.644.456.650 – netropsin MeSH D12.644.456.716 – pentagastrin MeSH D12.644.456.724 – pepstatins MeSH D12.644.456.726 – peptichemio MeSH D12.644.456.729 – peptide t MeSH D12.644.456.735 – phalloidine MeSH D12.644.456.745 – thyrotropin-releasing hormone MeSH D12.644.456.800 – tachykinins MeSH D12.644.456.800.354 – eledoisin MeSH D12.644.456.800.475 – kassinin MeSH D12.644.456.800.500 – neurokinin a MeSH D12.644.456.800.550 – neurokinin b MeSH D12.644.456.800.745 – physalaemin MeSH D12.644.456.800.866 – substance p MeSH D12.644.456.805 – technetium tc 99m mertiatide MeSH D12.644.456.810 – teprotide MeSH D12.644.456.830 – tetragastrin MeSH D12.644.456.835 – thymic factor, circulating MeSH D12.644.456.840 – tuftsin MeSH D12.644.456.925 – vasopressins MeSH D12.644.456.925.100 – argipressin MeSH D12.644.456.925.100.250 – deamino arginine vasopressin MeSH D12.644.456.925.325 – felypressin MeSH D12.644.456.925.480 – lypressin MeSH D12.644.456.925.700 – ornipressin MeSH D12.644.456.925.730 – oxytocin MeSH D12.644.456.925.940 – vasotocin
=== G04BE Drugs used in erectile dysfunction === G04BE01 Alprostadil G04BE02 Papaverine G04BE03 Sildenafil G04BE04 Yohimbin G04BE05 Phentolamine G04BE06 Moxisylyte G04BE07 Apomorphine G04BE08 Tadalafil G04BE09 Vardenafil G04BE10 Avanafil G04BE11 Udenafil G04BE30 Combinations G04BE52 Papaverine, combinations
== Function == As an isocitrate dehydrogenase, IDH1 catalyzes the reversible oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG) as part of the TCA cycle in glucose metabolism. IDH1 interacts with isocitrate and a divalent metal ion cofactor, typically Mg2+ or Mn2+, which plays a crucial role in stabilizing the negatively charged intermediates formed during the enzymatic reaction. It undergoes oxidation at the hydroxyl group on the C2 carbon, a reaction that removes electrons and produces oxalosuccinate. During this step, NAD(P)+ acts as an electron acceptor, transforming into NAD(P)H by gaining these electrons. Subsequently, oxalosuccinate undergoes decarboxylation, meaning it loses a carbon dioxide molecule, resulting in the formation of α-ketoglutarate. This step also allows for the concomitant reduction of nicotinamide adenine dinucleotide phosphate (NADP+) to reduced nicotinamide adenine dinucleotide phosphate (NADPH). Since NADPH and α-KG function in cellular detoxification processes in response to oxidative stress, IDH1 also indirectly participates in mitigating oxidative damage. In addition, IDH1 is key to β-oxidation of unsaturated fatty acids in the peroxisomes of liver cells. IDH1 also participates in the regulation of glucose-induced insulin secretion. Notably, IDH1 is the primary producer of NADPH in most tissues, especially in brain. Within cells, IDH1 has been observed to localize to the cytoplasm, peroxisome, and endoplasmic reticulum.
Sources: en.wikipedia.org
=== Buffer details === In general, as temperature decreases from 25 °C to 5 °C the pH of a tris buffer will increase an average of 0.03 units per degree. As temperature rises from 25 °C to 37 °C, the pH of a tris buffer will decrease an average of 0.025 units per degree. In general, a 10-fold increase in tris buffer concentration will lead to a 0.05 unit increase in pH and vice versa. Silver-containing single-junction pH electrodes (e.g., silver chloride electrodes) are incompatible with tris since an Ag-tris precipitate forms which clogs the junction. Double-junction electrodes are resistant to this problem, and non-silver containing electrodes are immune.
=== Primary metabolites === Primary metabolites are compounds made during the ordinary metabolism of the organism during the growth phase. A common example is ethanol or lactic acid, produced during glycolysis. Citric acid is produced by some strains of Aspergillus niger as part of the citric acid cycle to acidify their environment and prevent competitors from taking over. Glutamate is produced by some Micrococcus species, and some Corynebacterium species produce lysine, threonine, tryptophan and other amino acids. All of these compounds are produced during the normal "business" of the cell and released into the environment. There is therefore no need to rupture the cells for product recovery.
== Contaminant classes == Contaminants of emerging concern (CEC) can be broadly classed into several categories of chemicals such as pharmaceuticals and personal care products, cyanotoxins, nanoparticles, and flame retardants, among others. However, these classifications are constantly changing as new contaminants (or effects) are discovered and emerging contaminants from past years become less of a priority. These contaminants can generally be categorized as truly "new" contaminants that have only recently been discovered and researched, contaminants that were known about but their environmental effects were not fully understood, or "old" contaminants that have new information arising regarding their risks.
=== Kidney damage === Lithium has been associated with several forms of kidney injury. It is estimated that impaired urinary concentrating ability is present in at least half of individuals on chronic lithium therapy, a condition called lithium-induced nephrogenic diabetes insipidus, or lithium-induced AVP resistance. This occurs because lithium competes with the antidiuretic hormone in the kidney and increases water output into the urine. Clearance of lithium by the kidneys is usually successful with certain diuretic medications, including amiloride and triamterene. Continued use of lithium can lead to more serious kidney damage in an aggravated form of nephrogenic diabetes insipidus. Lithium specifically inhibits function of the aquaporin-2 water channel, leading to impaired reabsorption of water, polyuria, polydipsia, significant hypernatremia, which can lead to CNS symptoms such as confusion, lethargy, and coma. Chronic kidney disease, otherwise known as chronic renal insufficiency (CRI), occurs in 1–5% of people after 10–20 years of lithium treatment. End-stage renal disease occurs in 0.53% of people treated with lithium versus 0.2% in the general population. Kidney harm can be mitigated by keeping the lithium dose as low as possible and dosing lithium once per day at night. Multiple daily doses are associated with more kidney damage. Dosing lithium once per day allows for long periods where the kidney is exposed to low levels of lithium, which minimizes kidney harm.
Clematis is a genus of about 380 species within the buttercup family, Ranunculaceae. Their garden hybrids and cultivars have been popular among gardeners, beginning with Clematis 'Jackmanii', a garden staple since 1862. More cultivars are being produced constantly, mainly of Chinese and Japanese origin.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.